Prostate Biopsy and Radical Prostatectomy Gleason Score Correlation in Heterogenous Tumors: Proposal for a Composite Gleason Score
Recommended Citation
Arias-Stella JA, 3rd, Shah AB, Montoya-Cerrillo D, Williamson SR, and Gupta NS. Prostate biopsy and radical prostatectomy gleason score correlation in heterogenous tumors: Proposal for a composite gleason score. Am J Surg Pathol 2015; 39(9):1213-1218.
Document Type
Article
Publication Date
9-1-2015
Publication Title
The American journal of surgical pathology
Abstract
When prostate biopsy cores are separately identified in multiple containers, current recommendations are to grade each specimen individually. For treatment algorithms, the highest Gleason score (HGS) is typically used as the overall score, even if a lower score predominates. This practice has the potential to misrepresent the overall cancer in the entire gland for some patients and place them in a higher-grade group. We compare a novel composite Gleason score (CGS), integrating grade patterns from contiguous positive biopsy sites, with HGS to determine correlation with the radical prostatectomy (RP) Gleason score (GS). One hundred needle biopsy cases from 2008 to 2012 with >2 GSs in a biopsy set (eg, 3+3=6, 3+4=7, and 4+3=7) or more than a 1-step difference in GS (eg, 3+4=7 and 4+4=8 without 4+3=7) were analyzed. Grades were assigned using both methods (HGS and CGS) and compared with RPGS. Grade groups I to V were used to define downgrade and upgrade. Comparing HGS with RPGS, 31% remained the same and 69% had a change in GS (87% downgraded and 13% upgraded). Comparing CGS with RPGS, 59% remained the same and 41% had a change in GS (10% downgraded and 90% upgraded). Of the 2 methods, the CGS showed better overall correlation with RP (P2 grades are present in a biopsy set. CGS has a significantly lower rate of downgrade and predicts the RPGS more accurately than HGS.
Medical Subject Headings
Adult; Aged; Algorithms; Biopsy, Large-Core Needle; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Predictive Value of Tests; Prostatectomy; Prostatic Neoplasms; Reproducibility of Results; Treatment Outcome; Tumor Burden
PubMed ID
26274028
Volume
39
Issue
9
First Page
1213
Last Page
1218
